Evidence map›Paper›PMID 39821493›Full record

ArticleAddiction (Abingdon, England)2025

Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.

Noa Krawczyk, Megan Miller, Emma Yuanqi Gu, Natalia Irvine, Elisbel Ramirez, Julian Santaella-Tenorio, Thomas Lippincott, Michael Bogenschutz, Amanda M Bunting, Meredith C Meacham

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Noa KrawczykDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-7396-3938
Megan MillerDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Emma Yuanqi GuRady School of Management, University of California San Diego, La Jolla, CA, USA.
Natalia IrvineDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Elisbel RamirezDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.
Julian Santaella-TenorioDepartamento de Salud Pública y Epidemiología, Pontificia Universidad Javeriana, Cali, Colombia.
Thomas LippincottCenter for Language and Speech Processing, Johns Hopkins University, Baltimore, MD, USA.
Michael BogenschutzDepartment of Psychiatry, NYU Grossman School of Medicine; NYU Langone Center for Psychedelic Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0003-4530-3470
Amanda M BuntingDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, USA.ORCID https://orcid.org/0000-0002-2103-9655
Meredith C MeachamDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.

Funding

Development of a novel polysubstance assessment tool for vulnerable subpopulationsK01DA053435 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUNTING, AMANDA M · 2021 to 2025
$909k
Beyond Treatment Initiation: Enhancing Opioid Use Disorder Care Transitions Across Health System TouchpointsK01DA055758 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Noa Krawczyk · 2023 to 2026
$722k
National Institute On Drug Abuse of the National Institutes of Health K01DA046697National Institute On Drug Abuse of the National Institutes of Health K01DA055758NIDA NIH HHS K01 DA053435NIDA NIH HHS K01 DA055758
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these experiences are perceived to impact opioid use and what these lessons imply for future research and practice.

methodsWe conducted a qualitative study using the Reddit online community platform. We extracted posts that contained key psychedelic terms from the two most subscribed-to subreddits dedicated to discussions of OUD treatment (r/OpiatesRecovery and r/Methadone) from 2018 to 2021. We thematically analyzed content from 151 relevant posts and their respective comments.

resultsTwo prominent themes identified in discussions were perspectives on the effectiveness of psychedelics in treating OUD, and mechanisms through which psychedelics were thought to impact use and desire to use opioids. For many, psychedelics were deemed to have a strong impact on opioid use via multiple mechanisms, including alleviating physical symptoms of dependence, shifting motivations around desire to use opioids and addressing underlying mental health problems and reasons for use. Others saw the potential promise around psychedelics as exaggerated, acknowledging many people eventually return to use, or even considered psychedelics dangerous.

conclusionsThere appear to be diverse perspectives on the effects of using psychedelics to treat opioid use disorder and an urgent need for controlled studies to better understand the impact of different psychedelics on opioid use, how they may be used in the context of existing treatments and what strategies they must be combined with to ensure safety and effectiveness. Integrating the experiences of people who use drugs will help guide psychedelics research toward effective person-centered interventions to enhance health and wellness.

Indexed as

ibogaineon‐line communitiesopioidsopioid use disorderpeer supportpsilocybinpsychedelicspsychedelics‐assisted recoveryreddittreatment

Identifiers

PMID39821493
PMCPMC12951787

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.